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n March 2005, the Remission in Schizophrenia
Working Group (RSWG)
1 published a consensus defin-
ition of remission in schizophrenia, and developed oper-
ational criteria for its assessment (henceforth called the
RSWG criteria). These criteria define remission as a
level of core schizophrenia symptoms that does not
interfere with an individual’s behavior and is below that
required for a diagnosis of schizophrenia to be made
according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV). The criteria consist of two
elements: 
￿ A symptom-based criterion, which includes seven diag-
nostically relevant items from the DSM-IV. The seven
items specified in the DSM criteria were then cross-
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In March 2005, the Remission in Schizophrenia Working Group (RSWG) proposed a consensus definition of symptomatic
remission in schizophrenia and developed specific operational criteria for its assessment. They pointed out, however, that
the validity and the relationship to other outcome dimensions required further examination. This article reviews studies
on the validity, frequency, and predictors of symptomatic remission in schizophrenia and studies on patients’ perspectives.
These studies have demonstrated that the RSWG remission criteria appear achievable and sustainable for a significant pro-
portion of patients, and are related to a better overall symptomatic status and functional outcome and, to a less clear
extent, to a better quality of life and cognitive performance. However, achieving symptomatic remission is not automati-
cally concurrent with an adequate status in other outcome dimensions. The results of the present review suggest that the
RSWG remission criteria are valid and useful. As such, they should be consistently applied in clinical trials. However, the lack
of consensus definitions of functional remission and adequate quality of life hampers research on their predictive valid-
ity on these outcome dimensions. Future research should therefore search for criteria of these dimensions and test whether
the RSWG remission criteria consistently predict a “good” outcome with respect to functioning and quality of life.   
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PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 393matched to three different rating scales (Positive and
Negative Syndrome Scale [PANSS], the Scale for the
assessment of negative symptoms and positive symp-
toms [SANS/SAPS], and the Brief Psychiatric Rating
Scale [BPRS]). They correspond to eight items in the
PANSS, all of which have to be scored with a symptom
severity of ≤3 points (“mild” or better). The eight
symptoms include: (i) delusions; (ii) unusual thought
content; (iii) hallucinatory behavior; (iv) conceptual
disorganization; (v) mannerisms/posturing; (vi) blunted
affect; (vii) passive/apathetic social withdrawal; (viii)
lack of spontaneity and flow of conversation (Table I).
The symptom-based criterion can also be assessed
using the SANS/SAPS (severity ≤2 points). The BPRS
(severity ≤3 points) does not contain adequate repre-
sentation of negative symptoms and is therefore alone
not satisfactory for evaluating remission. The two neg-
ative symptoms not included in the BPRS (ie, “social
withdrawal” and “lack of spontaneity”) need to be
additionally assessed with PANSS or SANS when
BPRS is used.
￿ A time criterion, which requires that an individual
achieves the symptom-based criteria for a minimum of
6 months.
1
According to the RSWG, these criteria represent an
absolute threshold rather than a relative improvement
from a predefined baseline, which can be applied to
patients at all stages of the disease and that may facili-
tate cross-trial comparisons of interventions.
1-4 The cor-
responding European Working group concluded that
this definition will enhance the conduct of clinical inves-
tigations and reset expectations for treatment outcome
Clinical research
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Proposed remission criteria items
Scale for Assessment of Positive  Positive and Negative Brief Psychiatric Rating
Symptoms (SAPS) and Scale for  Syndrome Scale items Scale (BPRS) items
Assessment of Negative 
Symptoms (SANS) items
Dimension of DSM-IV ICD-10 Criterion Global rating Criterion Item  Criterion Item 
psychopathology criterion criterion item number number number
Psychoticism Delusions Delusions Delusions  (SAPS) 20 Delusions P1 Grandiosity 8
(reality Hallucinations Hallucinations Hallucinations 7 Hallucinatory P3 Hallucinatory 12
distortion) (SAPS) behavior behavior
Disorganization Disorganized  Breaks in train Positive formal 34 Conceptual P2 Conceptual 4
speech of thought,   thought disorder disorganization disorganization
incoherence or  (SAPS)
irrelevant speech
Grossly Catatonic Bizarre 25 Mannerisms/ G5 Mannerisms/ 7
disorganized behavior behavior posturing posturing
or catatonic (SAPS)
behavior
Negative  Negative Negative Affective 7 Blunted affect N1 Blunted affect 16
symptoms symptoms symptoms flattening
(psychomotor (SANS)
poverty)
Avolition-apathy 17 Social withdrawal N4 No clearly
(SANS) related  symptom
Anhedonia-asociality 22
(SANS)
Alogia (SANS) 13 Lack of spontaneity N6 No clearly 
related symptom
Table I. Proposed items for remission criteria of psychopathology dimensions and DSM-IV and ICD-10 criteria for schizophrenia.
a
a For symptomatic remission, maintenance over a 6-month period of simultaneous ratings of mild or less on all items is required. Rating scale
items are listed by item number. 
b Use of BPRS criteria may be complemented by use of the SANS criteria for evaluating overall remission.
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5 It is further essential to point out that
the remission criteria can be applied only to patients
who have previously been diagnosed using recognized
diagnostic criteria and that fulfilling the remission cri-
teria does not mean that the diagnosis is no longer
applicable.
5 Finally, the application of the criteria does
not imply or depend on any preconceptions about the
causal mechanisms underlying the illness, or those that
may have brought about remission.
5
The present article aims to review the literature pub-
lished since the introduction of the abovementioned
RSWG criteria in March 2005. The review especially
focuses on the validity of the applied remission criteria
and frequencies and predictors of remission. Further,
the patients’ perspectives on the proposed remission
criteria and implications for future research are dis-
cussed.
Since the publication of the remission criteria in March
2005, more than 50 articles on this topic have been pub-
lished. Reviewing these articles brings about various
problems: (i) many of the studies have used the symp-
tom-severity remission criteria omitting the time crite-
rion; (ii) some studies have used other outcome mea-
sures than the proposed PANSS, SANS/SAPS, or BPRS
scales (eg, CGI-S); (iii) some studies using the BPRS
have not assessed the two missing negative symptoms of
the severity criteria; (iv) There is a huge variation with
respect to duration of study period; (v) some studies suf-
fered from high dropout rates, if reported at all; (vi)
finally, there is a huge variation regarding sample selec-
tion (eg, acute inpatients vs stable outpatients, first-
episode vs multiple episode patients, schizophrenia vs
schizophrenia spectrum disorders, first-episode schizo-
phrenia vs first-episode psychosis including affective psy-
chosis, patients with comorbid substance use disorder in-
or excluded, major differences in symptom severity at
baseline, etc). Thus, comparability in terms of validity of
criteria as well as frequencies and predictors of remis-
sion is limited.
Validity of the remission criteria
For validation of remission criteria two different
approaches were used: (i) comparison of different defi-
nitions of symptomatic remission; and (ii) association of
the remission criteria with various outcome dimensions
including the overall symptomatic status, functional out-
come, quality of life, or other outcome criteria.
Comparison of different definitions of symptomatic
remission
To date, six post-hoc analyses have tested the proposed
RSWG criteria against other remission criteria in schiz-
ophrenia. 
In 2005 and 2006, Sethuraman et al
6 and Dunayevich et
al
7 compared the RSWG criteria with the criteria pro-
posed by Lieberman et al.
8 The latter require that a
patient achieve 50% reduction in BPRS total score,
BPRS scores of ≤3 concurrently on each of the follow-
ing BPRS psychosis items (unusual thought content,
suspiciousness, hallucinations, conceptual disorganiza-
tion, mannerisms, and posturing), and a Clinical Global
Impressions-Severity (CGI-S) score ≤3 for a minimum
of 8 weeks. The first post-hoc analysis by Sethuraman et
al
6 compared those two sets of criteria in 339 patients
followed over 28 weeks. The percentage of cumulative
time in remission was longer for the RSWG criteria.
The authors concluded that the criteria by Lieberman
et al are more stringent than the RSWG criteria. The
second post-hoc analysis by Dunayevich et al
7 used
pooled data from 6 double-blind, randomized trials
including 2771 patients. The proportion of patients who
met either remission criteria at any time during the
study period (8 to 52 weeks) was 66% (n=1825; 902
patients met RSWG criteria and 923 patients
Lieberman criteria). Mean reductions in PANSS total
score at week 24 were significantly lower in those ful-
filling RSWG criteria (-21.7 vs -42.6 in those fulfilling
Lieberman criteria). Further, improvements of quality
of life (QLS total score) were significantly lower with
RSWG criteria (+15.4 vs +19.6 with Lieberman crite-
ria). Regression analysis assessed the relative contribu-
tion of each of the components of the two remission cri-
teria (severity thresholds) to improvements in QLS
total score. BPRS change scores accounted for the
greatest effect on QLS total score improvements. The
authors concluded that the Lieberman criteria appeared
more stringent than the RSWG criteria, as almost all
patients achieving the Lieberman criteria also achieved
the RSWG criteria, while the converse was not appar-
ent.
In 2006, van Os and colleagues
9 assessed whether a
change in remission status would be associated with
changes in clinician-reported and patient-reported func-
tional outcomes. A total of 317 patients with a median
follow-up of 3.1 years were separated into patients with
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baseline. These groups were followed up for change in
remission status over time, and those who had changed
were compared with nonchanged individuals for
improvement in functional and quality of life outcomes.
Within this study, the RSWG criteria were compared
with RSWG criteria including the two PANSS items
“depression” and “suicidality.” Of the 145 patients, 35%
moved out of remission and 31% moved into remission.
When including depression and suicidality into the
remission criteria these frequencies did not change con-
siderably (37% and 29%). In both groups, change in
remission status was associated with large differences in
functional outcomes measured with the GAF and, to a
lesser extent, in quality of life. This led the authors to
conclude that the proposed remission criteria have “clin-
ical validity.”
In 2007, Leucht and colleagues reanalyzed 7 antipsy-
chotic trials (n=1708) of patients with schizophrenia
comparing three sets of remission criteria
10: (i) the
RSWG criteria; (ii) the Lieberman criteria; and (iii) the
criteria by Liberman et al.
11The latter require that the 9
BPRS items grandiosity, suspiciousness, unusual thought
content, hallucinations, conceptual disorganization,
bizarre behavior, self-neglect, blunted affect, and emo-
tional withdrawal be rated at not more than “moderate”
severity (score of ≥4). Comparable to the results by
Sethuraman et al
6 and Dunayevich et al,
7 the Lieberman
criteria were more stringent than the new RSWG crite-
ria (pooled remission frequencies at 1 year using sever-
ity criteria only = 38% vs 48%; LOCF). The criteria pro-
posed by Liberman et al
11 were less restrictive (pooled
remission frequencies at 1 year severity criteria only:
69%; LOCF). The authors concluded that a high strin-
gency does not mean the most adequate remission cri-
teria and that a major advantage of the new criteria is
that they have been conceptualized and are based on the
DSM-IV criteria for schizophrenia.
In 2008, Beitinger and colleagues reanalyzed six antipsy-
chotic trials (n=2463) of patients with schizophrenia
comparing two sets of remission criteria
12: the RSWG
criteria (full criteria in the three mid-term to long-term
studies; 28 to 52 weeks) using scores of ≤3 (“mild” or
better), ≤2 (“very mild” or better) or 1 (“not present”)
and the Lieberman criteria. Applying the RSWG crite-
ria to the mid-term studies with or without time criterion
resulted in the following frequencies: scores ≤3 (LOCF):
42%/11%, ≤2 (LOCF): 16%/1.8%, 1 (LOCF): 3.4%/0%;
in the long-term studies with or without time criterion:
scores ≤ 3 (LOCF): 42%/11%, ≤ 2 (LOCF): 13%/2%, 1
(LOCF): 5%/1%. Compared with the remission criteria
by Lieberman, the RSWG remission criteria were less
restrictive (week 28: 38% vs 60%). The authors con-
cluded that the results of more stringent thresholds
within the proposed remission criteria (scores of ≤2 or
lower) show that a score of mild or better is a “realistic
choice, more stringent thresholds yield remission fre-
quencies are not realistic.”
In 2009, Cassidy et al tested four sets of remission crite-
ria in 141 first-episode psychosis (FEP) patients for pre-
diction of functioning at the 2-year end point
13: (i) all
SAPS positive items (hallucinations, delusions, bizarre
behavior, positive formal thought disorder) rated ≤2
(severity) for 3 consecutive months; (ii) all SAPS posi-
tive items rated ≤2 for 6 consecutive months; (iii) all
SAPS positive and negative items (affective flattening,
alogia, avolition-apathy, anhedonia-asociality) rated ≤2
for 3 consecutive months; (iv) all SAPS positive and neg-
ative items rated ≤2 for 6 consecutive months. Totals of
94% and 84% of subjects for 3 and 6 months achieved
positive symptom remission, compared with 70% and
56% for positive and negative symptom remission,
respectively. Linear regression analyses showed that only
remission criteria containing both positive and negative
symptom criteria independently predicted functional
outcome. The authors concluded that consistent with the
consensus definition of remission, severity of both posi-
tive and negative symptoms is necessary although a 3-
month criterion had equal predictive validity to a 6-
month criterion.
In summary, the following conclusions were able to be
drawn:
￿ The new remission criteria by Andreasen et al
1 are less
stringent than the remission criteria by Lieberman et
al
8 and more stringent than the remission criteria by
Liberman et al.
11A higher stringency means that fewer
patients will fulfill the remission criteria, but if ful-
filled, the patients have a better clinical status. It is
therefore likely that remission criteria with higher
stringency will display a better predictive validity for
a broader outcome. However, it should be subject to
further discussion whether remission criteria with
lower stringency and longer time criterion
(Andreasen et al
1) or remission criteria with higher
stringency and shorter time criterion (Lieberman et
al
8) are to be preferred. The time criterion of 6 months
Clinical research
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was judged to be an appropriate cutoff because
“shorter cutoff periods would be insufficient to per-
mit validation of sustained and stable improvement.” 
5
Additionally, the value of the inclusion of a change
criterion is questionable (50% reduction in BPRS
total score by Lieberman et al
8) as remission rates
across samples will highly dependent on BPRS base-
line scores. 
￿ The rationale for selecting positive and negative symp-
tom items for the remission definition seems reason-
able because only definitions of remission containing
both positive and negative symptoms were predictive
of functional outcome, and both are core dimensions
of schizophrenia.
￿ The non-consideration of the symptom items depres-
sion and suicidality seems reasonable because there
inclusion did not change remission frequencies con-
siderably. This supports the assumption of van Os et
al,
5 who judged the exclusion of not diagnostically spe-
cific symptoms as appropriate because “they are influ-
enced by other factors, such as health care provision
and cultural issues, which show great geographic and
socioeconomic variability.”
￿ Increasing the severity threshold to ≤2 (“very mild” or
better) or 1 (“not present”) means that hardly any-
body will reach remission. This shows that a score of
‘mild’ or better is a realistic choice.
12
Association of symptomatic remission to other 
outcome dimensions
To date, 21 articles have published data on the relation
of RWSG remission status to other outcome dimensions
including the overall symptomatic status, functional out-
come, quality of life, or other outcome dimensions. Three
publications have assessed differences between already
remitted and nonremitted patients at baseline
14-16 and 14
publications within a follow-up period of 6 months to 5
years.
17-29Additionally, four publications have presented
data on the percentage of patients in symptomatic remis-
sion fulfilling other outcome criteria.
30-33 Table II gives an
overview on these 21 studies. Data were only included if
patients in actually remitted or nonremitted status were
directly compared. 
Overall, patients in symptomatic remission were found
to have a better overall symptomatic status, a better
functioning level, and, to a lesser clear extent, a better
quality of life and a better cognitive performance. 
Symptomatic status
All longitudinal studies which reported data on the rela-
tion of RSWG remission to the overall symptomatic sta-
tus (n=11) have found significantly better symptom sta-
tus at follow-up or greater psychopathology mean
change scores from baseline in remitted vs nonremitted
patients. Using the PANSS total score, the difference
between remitters and nonremitters range between 8
points to 25 points at follow-up with a mean difference
of approximately 18 points and a mean change score dif-
ference of 17 points (-32 vs. -17). The average PANSS
total score in remitters of 47 points underlines the low
psychopathology level related to RSWG remission, but
also suggests that the proposed criteria encompass
symptomatic remission and not complete absence of
symptoms. Important data with respect to the relation of
remission to overall psychopathology were published by
Opler et al.
20 They statistically validate the criteria for
remission using the PANSS scale in a 1-year trial assess-
ing 675 patients. Using a PANSS total score of 60 points
at time points > 6 months (8 and 12 months) the speci-
ficity of the remission criteria was 85%, ie, of the patients
who had a total score >60, 85% were classified as not in
remission. Sensitivity was also very high; 75% of patients
with scores of <60 were classified as in remission. The
authors concluded that these findings indicate that the
remission criteria are both sensitive and specific indica-
tors of the overall symptomatic status in schizophrenia.
Functional outcome
The five studies, which assessed the relation between
remission and functional outcome, all found a significantly
better functioning level in remitted vs nonremitted
patients. However, three studies
30-33 assessed the propor-
tion of patients in remission having a good functional
level and found that only 30% to 38% of remitted
patients at follow-up displayed an adequate functioning.
For the interpretation of this result it is important to know
that all three studies have set very stringent definitions of
adequate functioning, ie, GAF >80 points
30,31 or adequate
functioning in all 7 social roles in the GSDS scale
32 or ful-
fillment of vocational/occupation and independent living
criteria for at least 6 months.
33 On the other hand it is
arguable whether the chosen severity level “mild or bet-
ter” is really not associated with impaired functioning as
proposed in the original description of the criteria.
5 In
PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 397summary, it could be concluded that: (i) the fact of a sig-
nificant difference in functioning between remitters and
nonremitters does not necessarily mean that remitters are
functioning well; (ii) that the stringency of the function-
ing criterion strongly influence the rates of patients who
display an adequate functional outcome; and (iii) that
functioning in schizophrenia, in particular the voca-
tional/occupational status, is probably determined by oth-
ers factors independent from remission status, eg, com-
mon social and economic barriers of the general public in
a given country. Besides, patients’ functional outcome at
follow-up is strongly influenced by the previous func-
Clinical research
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Study N Assessment Remission criteria  Remitted vs nonremitted patients 
(1,2)
time-points assessed (NA = Not assessed; NS = Not specified; mc = mean change; 
(Baseline assessment  (SC = only severity ns = not significantly different)
[BA] and/or Follow-up  criteria; STC = severity Overall Functioning Quality of life Other
[in months]) AND time criteria) symptomatic outcome
or clinical status dimensions 
(3)
Studies comparing remitters with nonremitters
Helldin et al
14,15 211 BA SC NS NS NA BC, LCHC, LUN
Ciudad et al
16 1010 BA SC NS SCOS: 8 vs 11 MCS-12: 37 vs 44 BSC
Dunayevich et al
7 2771 6 SC PANSS mc: -22 vs -11 NA QLS mc: +15 vs +4
Buckley et al
17 184 6 SC NS NS NS NBC 
Emsley et al
18 462 12 STC PANSS mc: -41 vs -23 NA WQLS mc: 0.7 vs 0.3 NBC, LR
Kelly et al
19 43 12 STC BPRS: 28 vs 34 NA QLS: 57 vs 53 (ns)
Opler et al
20 675 12 STC PANSS: 52 vs 75  NA NA
Lasser et al
21 578 12 STC PANSS: 48 vs 67 NA NS
Kane et al
22 1283 12 STC CGI-I: 1.7 vs 3.7 NA NA
De Hert et al
23 341 24 STC PECC: 22 vs 38 GAF: 64 vs 44 NA
Wunderink et al
24 125 24 STC PANSS: 44 vs 52 GSDS: 5 vs 7 WHOQoL: 
98 vs 97 (ns)
Emsley et al
25 57 24 STC PANSS: 41 vs 66 NA NA
Addington &  240 36 STC PANSS pos & neg:  NA QLS: 85 vs 57
Addington
26 (LOCF) 19 vs 35
Helldin et al
27 211 60 SC PANSS: 49 vs 66 NA NA LCHC
Eberhard et al
28 115 60 STC NS GAF: 68 vs 52;  NA NBC
SCOS: 8 vs 9
Boden et al
29 76 60 SC NS Good function (%):  NS
73 vs 17
Studies assessing the percentage of patients in symptomatic remission fulfilling other outcome criteria
Study N Assessment  Assessed criteria Patients with adequate  Patients with adequate
time-points functioning in %  quality of life in %
Bobes et al
30, 452 12 SC 30 NA
San et al
31
Wunderink et al
32 125 24 STC 37 NA
Lambert et al
33 2960 36 STC 38 67
Table II. Relationship of symptomatic remission according to Andreasen et al
1 to other outcome criteria in schizophrenia (sorted according to assess-
ment time points). (1) Data are only reported when already remitted patients were compared with nonremitters at baseline; data of baseline
differences of patients who achieved remission or not at follow-up are not reported. (2) Scales: PANSS = Positive and Negative Syndrome
Scale; BPRS = Brief Psychiatric Rating Scale; CGI-I = Clinical Global Impression-Improvement Scale; SCOS = Strauss-Carpenter Outcomes Scale;
GAF = Global Assessment of Functioning Scale; GSDS = Groningen Social Disability Schedule; QLS = Quality of Life Scale; WQLS = Wisconsin
Quality of Life Scale; MCS-12 = Mental Component Score of the Medical Outcomes Study 12-item Short Form health survey. (3) Other out-
come dimensions: LCHC = Less consumption of health care; LR = Less relapse; BC = Better cognition; NBC = No better cognition; BDA =
Better drug attitude; LUN = Less unmet needs; BSC = Better social cognition
PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 398tioning level. For example, in a study by Catty et al,
34
assessing predictors of employment within an 18-month
follow-up period in 312 patients with psychotic disorders,
previous work history, and RSWG remission where sig-
nificant predictors of the number of hours employed
(P=0.001 and P<0.001, respectively). 
Quality of life
With respect to quality of life, 2 of 6 studies have found
no differences between remitted and nonremitted
patients; the others found a significantly better quality
of life in remitted patients. However, studies assessing
the frequency of remitted patients being in adequate
quality of life have found that only 60% to 70% of
patients display a satisfying quality of life.
Other outcome criteria
With respect to other outcome dimensions, 6 studies
have found that remitted vs nonremitted patients had
less consumption of health care resources, fewer relapses
in the respective follow-up period, and fewer unmet
needs. However, cognitive performance or neuropsy-
chological improvements were not related to remission
status in two of three studies. Further, the respective
studies on cognition do not answer the question whether
patients with remission display better cognitive func-
tioning or if patients with a higher level of cognitive per-
formance are more likely to meet remission criteria.
Frequencies of remission
The reported frequencies of the RSWG criteria could be
classified in following categories: (i) frequencies of the
cross-sectional symptom-severity remission criterion; (ii)
frequencies of patients fulfilling both the symptom-
severity and the time criterion; (iii) frequencies on the
stability of remission criteria over time. Studies were
restricted to those with at least 6-month follow-up (Table
III). As many studies especially focused on first-episode
patients they are reported separately in this section.
Since March 2005, more than 30 publications have
reported frequencies of fulfilled remission criteria in
first- and multiple episode psychosis/schizophrenia, 17
in multiple episode and 15 in first-episode patients
(Table III). Follow-up periods vary between 6 months
and 5 years. Completer frequencies (if reported) vary
between 40% and 80% with an average percentage of
approximately 60% of patients who completed the
respective follow-up remission assessment. The follow-
ing conclusions could be drawn (numbers represent
mean frequencies across studies):
￿ Many patients (45% to 70%) fulfill remission criteria
at some point during the respective follow-up period
with higher percentages when the time criterion is
omitted (61% vs 47%).
￿ At follow-up in completers, more patients fulfill remis-
sion criteria when the time criterion is omitted (56%
vs 44%).
￿ In first- and multiple episode completers, using the
severity remission criteria only, there is an increase of
remission frequencies between 6-month and 24-month
follow-ups (6-month: 46%, 12-month: 52%, 24-month:
63%) with 51% fulfilling the criteria at longer follow-
up periods. In first- and multiple episode completers,
using the severity and time remission criteria, there
also is an increase of remission frequencies over time
(6-month: 24%, 12-month: 39%, 24-month: 47%,
longer follow-up periods: 55%).
￿ Comparing first- and multiple episode completers,
using the severity remission criteria only, first-episode
patients display higher remission frequencies during
follow-up (61% vs 52%). Comparing first- and multi-
ple episode completers, using the severity and time
remission criteria, first-episode patients display higher
remission frequencies during follow-up (48% vs 43%).
￿ In approximately 75% of patients who reached remis-
sion (severity only or severity and time) at some point
during follow-up remission remains stable.
￿ Remission frequencies are higher in patients complet-
ing the follow-up assessments compared to patients
who dropped out of the study/treatment.
Predictors of remission
Attempts have been made to identify predictors of treat-
ment outcome in schizophrenia since the introduction of
effective treatment more than 50 years ago.
51 With
respect to remission, identification of specific premor-
bid, demographic, early improvement, and treatment
predictors could help to identify patients who will pos-
sibly achieve remission and to identify risk factors for
nonremission.
With respect to the proposed remission criteria, 12 stud-
ies to date have assessed predictors of remission using
Remission in schizophrenia - Lambert et al Dialogues in Clinical Neuroscience - Vol 12 . No. 3 . 2010
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Study N CO (%) Study  Only severity criteria (in %) Severity AND time criteria (in %) Stability
duration At 6 12 24 Longer At 6 12 24 Longer of
(in any months months months follow- any months months months follow- remission
months) time up 
(2) time up 
(2) (duration,
%) 
(1)
Multiple episode patients
Dunayevich et al
7 2771 1389 (50) 6 66 23 - - - - - - - - -
Buckley et al
17 184 NS 6 - 55 - - - - - - - - 6/84
Beitinger et al
12 (3)903/201 NS 12 - 42/61 42/63 - - - 11/20 11/32 - - -
Opler et al
20 675 427 (63) 12 - - 39 - - - - - - - -
Leucht et al
10 (3) 748 390 (52) 12 - - 48/68 - - - - 27/52 - - -
Kissling et al
35 715 508 (71) 12 - - 60 - - - - 31 - - 12/84
Lasser et al
21 578 437 (76) 12 - - - - - - - 41 - - 12/85
Bobes et al
30 452 376 (83) 12 - - 63 - - - - - - - 12/90
Rossi et al
36 347 243 (70) 12 - - 45 - - - 9 32 - - 12/63
Kane et al
22 1283 495 (39) 12 52 - - - - - - 29 - - -
Caton et al
37 (5) 186 NS 12 - - - - - - - 50 - - -
Cohen et al
38 198 NS 12 - - 49 - - - - - - - -
Lambert et al
39 529 211 (40) 18 - - - - - 33 - - - - -
Lambert et al
33 2960 2210 (75) 24 - - - - - - - - 47 - -
De Hert et al
23 341 24 - - - 44 - - - - 29 - 6/71; 24/63
Gasquet et al
40 933 563 (60) 36 - - - - - - - - - 61 -
van OS et al
9 317 NS 36 (3.1 y) 46 - - - - - - - - - 36/65
Eberhard et al
28 (6) 115 NS 60 - - - - - 59 - 54 62 59 -
Summary results 
(7) - 62% - 55 46 55 44 - 46 15 38 46 60 76
First-episode patients
Boter et al
41 498 NS 12 - - - - - - - 30 - - -
Emsley et al
18 462 NS 12 (381 d) 70 - - - - 24 - - - - -
Menezes et al
42 200 153 (77) 12 - - - - - - - 74 - - -
Bachmann et al
43 40 NS 14 - - 68 - - - - - - - -
Cassidy et al
13 207 141 (68) 24 56 - - - - - - - - - -
Petersen et al
44 547 369 (67) 24 - - - 62 - - - - 36 - -
Malla et al
45 107 NS 24 - - - 82 - - - - - - -
Wunderink et al
32 125 NS 24 - - - - - - - - 52 - -
Emsley et al
25 56 28 (49) 24 70 - - - - - - - 40 - 24 (83)
Novick et al
46 1009 701 (69) 24 - - - - - - - - 70 - -
Addington &  240 147 (61) 36 - - - - - - - - 37 - -
Addington
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Lambert et al
47 392 NS 36 70 - - - - 70 - - - 60 -
Boden et al
29 76 NS 60 - - - - 53 - - - - - -
De Haan et al
48 110 NS 60 - - - - - - 44 - - 38 -
Crumlish et al
49 (4) 118 67 (57) 96 - - - - 49 - - - - - -
Summary results - 64% - 67 - 68 72 51 47 44 52 47 49 83
Table III. Remission frequencies (in %) over various follow-up time-points in first- and multiple-episode patients (sorted according to duration of trial).
LOCF = Last-observation-carried-forward; CO = Completers only; NS = Not specified. (1) Stability of remission shows duration in months and
% of patients who reached remission and remained in remission within the study period; (2) Duration of follow-up is indicated by study dura-
tion; (3) Data report LOCF and CO frequencies; (4) Remission was fulfilled if all 30 PANSS items were Frequencyd ≤ 3; (5) 186 of 341 patients
assessed had a primary psychosis diagnosis; (6) Remission time criterion 12 months instead of 6 months; (7) CO data were used
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regression takes into account several predictive variables
simultaneously and controls for confounders, thus mod-
eling the predictive value of interest with higher accu-
racy than univariate analyses.
Overall, 6 most relevant predictors of symptomatic
remission were identified (Table IV): (i) shorter duration
of untreated psychosis (assessed in 6 of 12 studies, in 5 of
6 studies being a significant predictor of remission
[SPR]); (ii) better premorbid adjustment (assessed in 5
of 12 studies, in 4 of 5 studies SPR); (iii) lower psy-
chopathology or illness severity scores at baseline
(assessed in 11 of 12 studies, in 10 of 12 studies SPR); 
(iv) better functioning level at baseline (assessed in 9 of
12 studies, in 7 of 9 studies SPR); (v) early improvement
in symptoms or functioning (assessed in 7 of 12 studies,
in 5 of 5 studies SPR); and (vi) medication adherence
during treatment (assessed in 4 of 12 studies, in 3 of 4
studies SPR). Two other predictors were less clear related
to remission: (i) female gender (assessed in 11 of 12 stud-
ies, in 2 of 11 studies SPR); and (ii) lack of substance use
disorder at baseline or persistent substance use during
treatment (assessed in 6 of 12 studies, in only 3 of 6 stud-
ies SPR). Other previously identified predictors of out-
come in schizophrenia such as insight,
52 cognitive perfor-
mance,
53 age at onset,
54 biological variables,
54,55 or type of
interventions
56 were not assessed in follow-up studies in
the relation to the proposed remission criteria.
The 6 identified predictors were repeatedly found as rel-
evant even for long-term outcome studies in first- and
multiple-episode patients.
55,57-59This finding underlines
that predictors of remission are also relevant for the
overall outcome in schizophrenia.
51 This conclusion is
partly supported by studies, which assessed predictors of
remission, functional remission, and adequate quality of
life/subjective well-being simultaneously in a single
patient cohort. Lambert et al
33,47 and Novick et al
60 ana-
lyzed predictors of these three outcome dimensions
within the SOHO (Schizophrenia Outpatient Health
Outcome) study at 2
33 and 3 years' follow-up.
47,60 Overall,
symptomatic remission was mainly predicted by lower
illness severity at baseline, better functioning level at
baseline, early symptomatic improvement, medication
adherence and remitted substance use; functional remis-
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Study Study Premorbid, baseline, early improvement and treatment predictors related to symptomatic remission
duration Significant (S) or not significant (NS) predictor of symptomatic remission in multivariate regression models
(in - = Not assessed
months) Short(er) duration Better Lower psychpathol- Better Early symptomatic, Medication
in untreated premorbid ogy or illness functioning functional or nonadherence
psychosis (DUP) adjustment severity score level quality of life during
at baseline at baseline improvement/ treatment
remission
Emsley et al
18 12 S 
(2) NS S (neg symp)
(3) - S (symptoms)** -
Rossi et al
36 12 - - S*** NS - -
Caton et al
37 12 S
(4) S
(4) S
(4) -- -
Lambert et al
39 18 S* - S*** S** S (symptoms)*** -
Malla et al
45 24 S** S* - - - S***
Lambert et al
33 (1) 24 - - S*** S** S (symptoms)*** S**
Novick et al
46 (1) 24 - - S** S* - -
Emsley et al
25 24 S
(4) S (education status)
(4) NS S, (marital status)
(4) S (symptoms)
(4) -
Lambert et al
47 (1) 36 - - NS NS S*** (symptoms) NS
Gasquet et al
40 (1) 36 - - S
(4) S, (employment)
(4) --
Novick et al
50 (1) 36 - - S*** S*** - S***
Addington &  36 NS S* S*** - - -
Addington
26
Table IV. Most relevant predictors of remission defined as severity and time criteria as proposed by Andreasen et al
1 (sorted according to duration of
trial). (1) These studies used CGI-Schizophrenia criteria (CGI-SCH overall, positive, negative, cognitive and depressive subscores ≤ 3) instead
of the PANSS severity items. (2) * for schizophreniform / schizoaffective disorder and ** for schizophrenia. (3) For schizophrenia only. (4) No
P values provided for multivariate model, at least P<0.05. * = significant at P<0.05; ** = P≤0.01; *** = P≤0.001
PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:40  Page 401sion by younger age, better functioning level at baseline
and early functional remission; and adequate quality of
life by younger age, lower illness severity at baseline, bet-
ter functioning level at baseline, early symptomatic and
quality of life remission, and medication adherence. Full
remission (fulfilling all three dimensions for ≥6 months)
and recovery (fulfilling all three dimensions for ≥24
months) was mainly predicted by younger age, better
functioning level at baseline, and early improvement
within all three outcome dimensions. Therefore, these
results suggest that predictors of symptomatic remission
are partly also predictors for the overall outcome in
schizophrenia with baseline functioning playing an
important predictive role.
Several limitations of these findings have to be
addressed: (i) results are hampered by a large variation
regarding aspects such as sample selection and collec-
tion, assessment methods used or duration of study
period; (ii) aspects of type and intensity of treatment are
rarely assessed. The meta-analysis of Menezes et al
56 of
37 longitudinal outcome studies of first-episode non-
affective psychosis highlights the importance of these
two aspects. They failed to confirm previously reported
variables such as duration of untreated psychosis or age
at onset as significant outcome predictors, and found
that a favorable outcome were mainly related to com-
bined pharmacotherapeutic and psychosocial interven-
tions as well as lack of epidemiologic representativeness
of the sample. These findings suggest that future studies
on remission and its predictors should control for treat-
ment aspects and should aim to assess cohorts as repre-
sentative as possible.
Remission as perceived by patients, 
relatives, and psychiatrists
Patients, relatives and psychiatrists perspectives regard-
ing the RSWG remission criteria have rarely been
explored. In a study by Karow et al,
61 44% of 131
patients were in symptomatic remission according to the
RSWG symptom based remission criterion. However,
only 39% of these remitted patients judged themselves
as remitted, 32% were remitted according to their rela-
tives, and 61% according to the psychiatrists. Only in
18% of all cases, patients, relatives and psychiatrists
agreed in their assessment of patients’ remission.
Remission as assessed by the patients was most diver-
gent from RSWG remission with only 43% accordance,
whereas remission as assessed by the psychiatrists
showed the best accordance (80%). Relatives’ estimates
showed 52% accordance with the RSWG remission, yet
the highest accordance with RSWG nonremission
(84%).
Comparisons of the different assessments of remission
with other clinical measures showed a preference on the
patients’ side for subjective well-being and on the psy-
chiatrists’ side for the level of symptoms of psychosis.
The results indicated that patients, their relatives, and
psychiatrists differ highly in their understanding what
state of symptom reduction should be called “sympto-
matic remission.”
Conclusions
The present review shows that the consensus RSWG
remission criteria are clinically meaningful; they appear
achievable for a significant proportion of patients in rou-
tine clinical practice and are applicable across the course
of the illness. Further, validation studies have shown that
they are related to a good overall symptomatic status
with low levels of overall psychopathology or illness
severity, to a better functional status compared with non-
remitted patients and, to a less clear extent, to a better
quality of life or cognitive performance. On the other
hand, these studies have also consistently shown that
patients in remission do not automatically have an “ade-
quate” functional level or quality of life. Both results
support the assumption that patients being in sympto-
matic remission display a better overall illness state,
although it has to be acknowledged that being in symp-
tomatic remission does not necessarily mean that the
patient is doing well, because other components of the
illness (such as enduring affective or cognitive symp-
toms) may lead to functional impairments or poor qual-
ity of life. Research in this field is among others ham-
pered by the lack of consensus definitions of an
“adequate” functional and quality of life status in schiz-
ophrenia. Future research should therefore search for
such criteria and test whether the fulfillment of the
RSWG remission criteria is consistently related to an
“adequate” functional and quality of life status. In sum-
mary, results of this review supports the conclusion of
van Os and colleagues, who stated that remission is a
necessary (but not sufficient) step towards recovery.
5
With respect to the comparison of different remission
definitions, there are considerably differences between
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ria (ie, Lieberman et al
8 or Liberman et al
11) with respect
to symptoms included, inclusion of an improvement cri-
terion, severity thresholds and duration or inclusion of
the time criterion. These differences hamper the popu-
lations these criteria could be applied for and the com-
parability of results. With respect to stringency of the cri-
teria, data have shown that a realistic proportion of
patients could fulfill the RSWG remission criteria and
that more stringent criteria (eg, lower thresholds for the
severity criteria of ≤2 or =1) are not realistic in clinical
settings. The inclusion of an improvement criterion (eg,
achievement of 50% reduction in BPRS total score from
baseline), as applied in the criteria by Lieberman et al,
8
increases the stringency and thereby the predictive valid-
ity for other outcome dimensions; however, only a
minority of patients could reach such on outcome.
Further, such a criterion implicates that studies includ-
ing varying patient populations regarding baseline psy-
chopathology are difficult (if not impossible) to com-
pare. Applying less stringent severity criteria as
proposed by Liberman et al
11 (“moderately ill” or bet-
ter) leads to higher frequencies of patients in remission,
but lowers the predictive validity for other outcome
dimensions; further, its validity was hitherto insuffi-
ciently studied. 
Of note, the inclusion of other symptoms such as depres-
sion and suicidality in the set of remission items did not
change the remission frequencies considerably. This
result supports the conceptualization of the RSWG cri-
teria, which used the most diagnostically specific items
of the Positive and Negative Symptoms Scale (PANSS)
to define remission.
5 Items such as depression or anxiety
relate to symptoms that are not diagnostic for schizo-
phrenia. Conceptually, it may be subject of further dis-
cussion, whether depression and anxiety should be
included in the RSWG criteria, as these dimensions were
linked to poor quality of life. It may, however, be argued
that these dimensions play a more import role in the
broader concept of recovery.
The applied 6-month time criterion of the RSWG
remission criteria is still a matter of debate. The only
available study to date has found that a 3-month crite-
rion has a comparable predictive validity for the stabil-
ity of remission over time.
13 Further, studies on early
response and the proportion of patients with early
response being in stable remission over time have
shown that even shorter time periods are predictive for
the stability of remission.
62,63Applying shorter time peri-
ods is additionally supported by the fact that approxi-
mately 75% of patients reaching the symptom severity-
criteria threshold without fulfilling the 6-month time
criterion remain in remission throughout a 6- to 60-
month follow-up period. However, this result is possi-
bly hampered by large assessment gaps facing the prob-
lem to investigate remission status retrospectively over
a 6- to 12-month time period. Further, it contradicts the
known high cumulative relapse rates in schizophrenia.
64
As such, the applicability of the 6-month criterion ver-
sus shorter time criteria should be assessed in future
prospective studies with short, possibly 1- to 3-monthly
follow-up intervals. Finally, the RSWG proposed
PANSS, and SAPS/SANS for the assessment of the
remission criteria. However, Leucht et al proposed that
in pragmatic trials the Clinical Global Impression Scale
(CGI) could also be used (scores ≤3).
4
With respect to frequencies of fulfilled remission crite-
ria in different patient populations, this review has
shown that 40% to 60% of patients with schizophrenia
can reach remission, that remission frequencies differ
markedly between different patient populations (eg,
acute versus stabilized at baseline), that more patients
reaching remission when the time criterion is omitted,
that cumulative frequencies of remission increase over
time, that first-episode when compared with mainly mul-
tiple-episode cohorts display higher frequencies of
remission and that patients who drop out of study and/or
treatment are less likely to be in remission. These results
have several implications for future research and clini-
cal settings: 
￿ In future research, patient remission frequencies
should be presented in the following categories
3: (i)
patients who were not in remission at baseline and
who achieved remission during the study; (ii) patients
who were in remission at baseline and remained in
remission during the study; (iii) patients who were in
remission at baseline, which was not sustained during
the course of the study. In studies with at least 6-month
follow-up, frequencies 2 and 3 should be separated into
patients who reached the symptom-severity criteria
only and those who reached the symptom-severity and
time criteria.
￿ Dropout rates should be reported and adequate mea-
sures taken to account for their clinical status at
dropout, when remission rates are presented. As
patients who drop out are less likely to be in remission,
Remission in schizophrenia - Lambert et al Dialogues in Clinical Neuroscience - Vol 12 . No. 3 . 2010
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the subsequent course of illness. Studies on service dis-
engagement have repeatedly shown that these patients
are in a poor mental state at time of disengagement.
65,66
These results supports that studies presenting fre-
quencies of remission on the full cohort should possi-
bly count all or the majority of lost-to-follow-up
patients as nonremitters (if not better known).
￿ As it is unclear how frequently assessments should be
performed over the course of a study, a balance should
be kept between gaining the optimal amount of clinical
data and designing a practical clinical trial.
3 It would be
interesting to see methodological studies on the con-
gruence between shorter (monthly) versus longer (3-
monthly or longer) interval assessments. It is certainly
difficult to engage patients in monthly assessments and
potentially unreliable to assess them only 3-monthly.
With respect to predictors of symptomatic remission, the
present study revealed several modifiable and unmodi-
fiable factors. Unmodifiable predictors comprise a
shorter duration of untreated psychosis, a better pre-
morbid functioning, lower psychopathology or illness
severity levels at baseline, and a better functioning at
baseline (all factors are indirectly modifiable by com-
munity education campaigns); modifiable predictors
include early remission and medication adherence.
Other predictors including comorbid substance use or
female gender were less conclusively related or not
tested for their predictive validity. Further, other known
predictors of outcome in schizophrenia were rarely or
not tested in multivariate analysis.
With respect to future research, Lasser and colleagues
3
proposed a set of modifiable and unmodifiable factors,
which should be assessed in studies on remission in
schizophrenia. Beside their proposal and the assessment
of the abovementioned predictors some other important
recommendations should be addressed:
(i) As the diagnosis of schizophrenia was linked to poor
overall outcome compared with other schizophrenia-spec-
trum disorders, diagnosis should be optimally separated
into the three most prevalent schizophrenia-spectrum
DSM-IV diagnoses, ie, schizophrenia, schizophreniform
disorder, and schizoaffective disorder. As the concept of
remission is not applicable for bipolar I disorder or severe
depression with psychotic features, they should be
excluded from analysis if first-episode cohorts are assessed.
In long-term studies assessing remission in first-episode
psychosis, diagnostic stability testing is also needed.
67
(ii) Beside the abovementioned predictors, the latest
research has shown that baseline and early change
scores of subjective wellbeing have a high predictive
validity for symptomatic remission and recovery.
48,62,68As
such, the SWN-K scale at baseline and early follow-up
may be an interesting predictor to consider.
(iii) As Menezes et al
56 highlighted the importance of
combined pharmacotherapeutic and psychosocial inter-
ventions as well as lack of epidemiologic representa-
tiveness as predictors, these aspects should be assessed
or clearly described.
(iv) Whenever possible the relation of symptomatic
remission to functional status or quality of life and their
predictors should be assessed simultaneously. Because
of the lack of consensus criteria with respect to “ade-
quate” functioning and quality life, researchers should
replicate findings of studies already applying criteria for
functional outcome and should use quality of life scales
specific for schizophrenia.
In summary, more than 50 prospective or post-hoc stud-
ies to date have applied the RSWG remission criteria to
different patient populations in different settings using
the symptom-severity criteria only or the complete
remission criteria. The result that 40% to 60% of pa-
tients can achieve symptomatic remission during various
follow-up periods supports the hope of the RSWG that
remission is an achievable objective for a significant pro-
portion of patients with a diagnosis of schizophrenia.
However, as only about 10 out of 50 studies assessed the
relationship of symptomatic remission to functional out-
come and cognition, the hope of the RSWG that the
availability of a validated remission measure would stim-
ulate new studies on cognition and functional outcomes
has only partly been fulfilled. This also holds true for
studies on the association of symptomatic remission with
quality of life. It is further important to know that none
of the 50 studies to date have assessed the influence of
differing clinical services or different type of interven-
tions on the proposed remission criteria. Finally, only
one study to date has assessed the congruence between
RSWG remission and remission as perceived by
patients, relatives, and professionals. This is surprising
considering the hope of the RSWG was that the devel-
opment of remission criteria should facilitate the dia-
logue on treatment expectations among physicians,
patients and carers, health care administrators, and pol-
icy makers. The authors hope that the present article
supports future research in this area. ❏
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La remisión en la esquizofrenia: validez, 
frecuencia, predictores y percepción de los
pacientes después de cinco años
En marzo de 2005 el grupo de trabajo sobre remi-
sión en esquizofrenia (GTRE) propuso una defini-
ción de consenso de la remisión sintomática en la
esquizofrenia y desarrolló criterios operacionales
para su evaluación. Sin embargo, se señaló que la
validez y la relación con otras dimensiones de la
evolución requerían de futuras revisiones. Este
artículo reseña estudios acerca de la validez, fre-
cuencia y predictores de la remisión sintomática
en la esquizofrenia y estudios sobre la percepción
de los pacientes. Estos estudios han demostrado
que los criterios de remisión del GTRE parecen
alcanzables y sustentables para un grupo impor-
tante de pacientes y se relacionan globalmente
con un mejor estado sintomático y una mejor evo-
lución funcional, y en menor medida con una
mejor calidad de vida y un mayor rendimiento
cognitivo. Sin embargo, el alcanzar la remisión
sintomática no es simultánea en forma automá-
tica con un adecuado estado en otras dimensio-
nes de la evolución. Los resultados de la presente
revisión sugieren que los criterios de remisión del
GTRE son válidos y útiles. Como tal, debieran ser
aplicados sistemáticamente en los ensayos clíni-
cos. Sin embargo,  la obtención de una remisión
sintomática no coincide en forma automática con
una definición que satisfaga las otras definiciones
pronósticas.. La investigación futura debiera, por
lo tanto, buscar criterios de estas dimensiones y
probar si los criterios de remisión del GTRE predi-
cen sistemáticamente una “buena” evolución en
relación con el funcionamiento y la calidad de
vida. 
La rémission dans la schizophrénie : validité,
fréquence, prévisions et perspectives des
patients à 5 ans 
En mars 2005, le groupe de travail sur la rémission
dans la schizophrénie (GTRS) a proposé une défini-
tion consensuelle de la rémission symptomatique
dans la schizophrénie et développé des critères opé-
rationnels spécifiques pour son évaluation. Ils ont
souligné, cependant, que la validité de la définition
et les relations avec les autres dimensions pronos-
tiques nécessitaient une analyse plus vaste. Cet article
passe en revue des études sur la validité, la fréquence
et les prévisions d’une rémission symptomatique
dans la schizophrénie ainsi que des études sur les
perspectives des patients. Ces études ont démontré
que les critères de rémission du GTRS semblaient réa-
lisables et durables pour un nombre significatif de
patients. Ces critères sont de plus liés à un état  symp-
tomatique globalement meilleur, ainsi qu'un meilleur
état fonctionnel, et, dans une moindre mesure, à une
qualité de vie et à une performance cognitive
meilleures. Cependant, l’obtention d’une rémission
symptomatique ne coïncide pas automatiquement
avec une définition satisfaisante pour les autres
dimensions pronostiques. Les résultats de cette ana-
lyse suggèrent que les critères de rémission du GTRS
sont valables et utiles. Ils devraient donc être systé-
matiquement appliqués dans les études cliniques.
Cependant, le manque de définition consensuelle
pour la rémission fonctionnelle et pour une qualité
de vie satisfaisante entrave la recherche sur la vali-
dité prédictive de ces dimensions pronostiques. Il fau-
drait donc faire des recherches pour déterminer l’im-
portance de ces dimensions et voir si les critères de
rémission du GTRS prévoient de façon fiable une 
« bonne » évolution respectant le fonctionnement
et la qualité de vie. 
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